Basic Information
| LncRNA/CircRNA Name | LINC00894-002 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Tamoxifen | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (MCF-7/WT and MCF-7/TamR) |
| Expression Pattern | down-regulated |
| Function Description | LINC00894-002 exhibits the most sophisticated network pattern and is the most downregulated lncRNA in MCF-7/TamR cells. Moreover,LINC00894-002 is directly upregulated by ERa.Knocking down LINC00894-002 downregulates expression of miR-200a-3p and miR-200b-3p, upregulates the expression of TGF-B2 and ZEB1,and finally contributes to TamR.Herein, we report the first case of an inhibitory lncRNA against TamR through the miR-200-TGF-B2-ZEB1 signaling pathway. |
| Pubmed ID | 29738694 |
| Year | 2018 |
| Title | Downregulation of LINC00894-002 Contributes to Tamoxifen Resistance by Enhancing the TGF-B Signaling Pathway. |
External Links
| Links for LINC00894-002 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |